Global Trust Asset Management LLC Sells 255 Shares of Bristol-Myers Squibb Co (BMY)

Share on StockTwits

Global Trust Asset Management LLC decreased its position in shares of Bristol-Myers Squibb Co (NYSE:BMY) by 20.3% during the 1st quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 1,000 shares of the biopharmaceutical company’s stock after selling 255 shares during the quarter. Global Trust Asset Management LLC’s holdings in Bristol-Myers Squibb were worth $48,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Vanguard Group Inc raised its position in Bristol-Myers Squibb by 1.0% during the 3rd quarter. Vanguard Group Inc now owns 128,376,159 shares of the biopharmaceutical company’s stock worth $7,969,593,000 after purchasing an additional 1,229,553 shares during the last quarter. BlackRock Inc. raised its position in Bristol-Myers Squibb by 0.9% during the 4th quarter. BlackRock Inc. now owns 115,573,078 shares of the biopharmaceutical company’s stock worth $6,007,489,000 after purchasing an additional 999,193 shares during the last quarter. Dodge & Cox raised its position in Bristol-Myers Squibb by 0.8% during the 3rd quarter. Dodge & Cox now owns 32,969,186 shares of the biopharmaceutical company’s stock worth $2,046,727,000 after purchasing an additional 264,100 shares during the last quarter. Northern Trust Corp raised its position in Bristol-Myers Squibb by 4.4% during the 4th quarter. Northern Trust Corp now owns 22,576,884 shares of the biopharmaceutical company’s stock worth $1,173,547,000 after purchasing an additional 954,877 shares during the last quarter. Finally, Bank of New York Mellon Corp raised its position in Bristol-Myers Squibb by 1.1% during the 4th quarter. Bank of New York Mellon Corp now owns 17,303,884 shares of the biopharmaceutical company’s stock worth $899,456,000 after purchasing an additional 180,711 shares during the last quarter. 74.28% of the stock is currently owned by institutional investors.

BMY stock opened at $45.52 on Friday. Bristol-Myers Squibb Co has a 1-year low of $44.30 and a 1-year high of $63.69. The company has a debt-to-equity ratio of 0.40, a current ratio of 1.61 and a quick ratio of 1.50. The stock has a market capitalization of $74.38 billion, a PE ratio of 11.44, a price-to-earnings-growth ratio of 2.34 and a beta of 0.79.

Bristol-Myers Squibb (NYSE:BMY) last posted its quarterly earnings data on Thursday, January 24th. The biopharmaceutical company reported $0.94 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $0.85 by $0.09. Bristol-Myers Squibb had a return on equity of 48.99% and a net margin of 21.95%. The firm had revenue of $5.97 billion during the quarter, compared to analyst estimates of $5.95 billion. During the same period last year, the company posted $0.68 EPS. The business’s quarterly revenue was up 9.6% on a year-over-year basis. Analysts expect that Bristol-Myers Squibb Co will post 4.16 earnings per share for the current year.

The firm also recently disclosed a quarterly dividend, which will be paid on Wednesday, May 1st. Stockholders of record on Friday, April 5th will be given a $0.41 dividend. This represents a $1.64 annualized dividend and a dividend yield of 3.60%. The ex-dividend date of this dividend is Thursday, April 4th. Bristol-Myers Squibb’s dividend payout ratio (DPR) is presently 41.21%.

BMY has been the subject of several analyst reports. BMO Capital Markets reaffirmed a “buy” rating and set a $60.00 target price on shares of Bristol-Myers Squibb in a research report on Thursday, January 3rd. Zacks Investment Research raised Bristol-Myers Squibb from a “hold” rating to a “buy” rating and set a $60.00 target price for the company in a research report on Tuesday, March 5th. Societe Generale raised Bristol-Myers Squibb from a “sell” rating to a “buy” rating in a research report on Tuesday, January 15th. Credit Suisse Group reaffirmed a “hold” rating and set a $59.00 target price on shares of Bristol-Myers Squibb in a research report on Friday, February 15th. Finally, Bank of America set a $53.00 target price on Bristol-Myers Squibb and gave the stock a “hold” rating in a research report on Friday, January 25th. One equities research analyst has rated the stock with a sell rating, eleven have given a hold rating and six have assigned a buy rating to the company’s stock. The stock presently has an average rating of “Hold” and a consensus target price of $59.14.

WARNING: This report was originally reported by Zolmax and is the property of of Zolmax. If you are reading this report on another publication, it was illegally stolen and republished in violation of U.S. & international copyright legislation. The original version of this report can be read at https://zolmax.com/investing/global-trust-asset-management-llc-sells-255-shares-of-bristol-myers-squibb-co-bmy/3052092.html.

Bristol-Myers Squibb Company Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. The company offers drugs in oncology, immunoscience, cardiovascular, and fibrotic diseases. The company's products include Opdivo, a biological product for anti-cancer indications; Eliquis, an oral inhibitor targeted at stroke prevention in adult patients with non-valvular atrial fibrillation, and the prevention and treatment of venous thromboembolic disorders; and Orencia, a biological product for adult patients with moderately to severely active RA and prostate-specific antigen, as well as reducing signs and symptoms in certain pediatric patients with moderately to severely active polyarticular juvenile idiopathic arthritis.

Featured Story: Institutional Investors

Want to see what other hedge funds are holding BMY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bristol-Myers Squibb Co (NYSE:BMY).

Institutional Ownership by Quarter for Bristol-Myers Squibb (NYSE:BMY)

Receive News & Ratings for Bristol-Myers Squibb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Orezone Gold  Hits New 12-Month Low at $0.41
Orezone Gold Hits New 12-Month Low at $0.41
Jack Henry & Associates, Inc.  Shares Bought by Raymond James Financial Services Advisors Inc.
Jack Henry & Associates, Inc. Shares Bought by Raymond James Financial Services Advisors Inc.
Raymond James Financial Services Advisors Inc. Has $5.22 Million Position in Invesco Ultra Short Duration ETF
Raymond James Financial Services Advisors Inc. Has $5.22 Million Position in Invesco Ultra Short Duration ETF
Greenleaf Trust Acquires 251 Shares of Sempra Energy
Greenleaf Trust Acquires 251 Shares of Sempra Energy
Ross Stores  Updates Q2 Earnings Guidance
Ross Stores Updates Q2 Earnings Guidance
Target Co.  Shares Sold by National Asset Management Inc.
Target Co. Shares Sold by National Asset Management Inc.


 
© 2006-2019 Zolmax.